Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1974 Apr;71(4):1422–1426. doi: 10.1073/pnas.71.4.1422

Epstein-Barr Virus-Associated Membrane-Reactive Antibodies During Long Term Survival After Burkitt's Lymphoma

Peter Gunvén *, George Klein *, Peter Clifford †,‡, Surjit Singh †
PMCID: PMC388241  PMID: 4364538

Abstract

Antibodies to Epstein-Barr virus associated cell membrane antigens persisted or slowly decreased during prolonged uncomplicated survival of patients with Burkitt's lymphoma in remission. Serum was sampled from four patients within 6 months before recurrence occurring after the first year and preceded by remission during more than 6 months. Rapid and significant decreases of the antibodies before clinical recognition of the recurrences were found in three patients. The fourth patient had slowly increasing titers before relapse. Immune stimulant treatment during remission, with BCG (Bacille Calmette Guérin vaccine) or BCG + Bordetella pertussis, temporarily increased the antibody levels. Possible mechanisms for the observed titer changes before recurrence are discussed.

Keywords: immunofluorescence, tumor recurrence, immune complex, immunoresistance

Full text

PDF
1422

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldwin R. W., Price M. R., Robins R. A. Blocking of lymphocyte-mediated cytotoxicity for rat hepatoma cells by tumour-specific antigen-antibody complexes. Nat New Biol. 1972 Aug 9;238(84):185–186. doi: 10.1038/newbio238185a0. [DOI] [PubMed] [Google Scholar]
  2. Clifford P., Gripenberg U., Klein E., Fenyo E. M., Manolov G. Treatment of Burkitt's lymphoma. Lancet. 1968 Aug 31;2(7566):517–518. doi: 10.1016/s0140-6736(68)90681-8. [DOI] [PubMed] [Google Scholar]
  3. Clifford P., Singh S., Stjernswärd J., Klein G. Long-term survival of patients with Burkitt's lymphoma: an assessment of treatment and other factors which may relate to survival. Cancer Res. 1967 Dec;27(12):2578–2615. [PubMed] [Google Scholar]
  4. Einhorn N., Henle G., Henle W., Klein G., Clifford P. Effect of local radiotherapy on the antibody levels against EBV-induced early and capsid antigens (EA and VCA) in patients with certain malignant tumours. Int J Cancer. 1972 Jan 15;9(1):182–192. doi: 10.1002/ijc.2910090121. [DOI] [PubMed] [Google Scholar]
  5. Goldstein G., Klein G., Pearson G., Clifford P. Direct membrane immunofluorescence reaction of Burkitt's lymphoma cells in culture. Cancer Res. 1969 Apr;29(4):749–752. [PubMed] [Google Scholar]
  6. Gunvén P., Klein G. Blocking of direct membrane immunofluorescence in titration of membrane-reactive antibodies associated with Epstein-Barr virus. J Natl Cancer Inst. 1971 Sep;47(3):539–548. [PubMed] [Google Scholar]
  7. Gunvén P., Klein G., Henle G., Henle W., Clifford P. Epstein-Barr virus in Burkitt's lymphoma and nasopharyngeal carcinoma. Antibodies to EBV associated membrane and viral capsid antigens in Burkitt lymphoma patients. Nature. 1970 Dec 12;228(5276):1053–1056. doi: 10.1038/2281053a0. [DOI] [PubMed] [Google Scholar]
  8. Gunvén P., Klein G., Henle W., Henle G., Rocchi G., Hewetson J. F., Guerra A., Clifford P., Singh S., Demissie A. Immunological studies on a case of recurrent Burkitt's lymphoma during immune stimulant treatment. Int J Cancer. 1973 Jul 15;12(1):115–123. doi: 10.1002/ijc.2910120112. [DOI] [PubMed] [Google Scholar]
  9. Gunvén P., Klein G., Onyango J., Henle G., Henle W., Clifford P., Singh S., Demissie A., Svedmyr A. Antibodies associated with Epstein-Barr virus in Burkitt's lymphoma during injections of BCG or irradiated autochthonous tumor cells. J Natl Cancer Inst. 1973 Jul;51(1):45–56. doi: 10.1093/jnci/51.1.45. [DOI] [PubMed] [Google Scholar]
  10. HAUSCHKA T. S., GRINNELL S. T., REVESZ L., KLEIN G. Quantitative studies on the multiplication of neoplastic cells in vivo. IV. Influence of doubled chromosome number on growth rate and final population size. J Natl Cancer Inst. 1957 Jul;19(1):13–31. [PubMed] [Google Scholar]
  11. Henle G., Henle W., Clifford P., Diehl V., Kafuko G. W., Kirya B. G., Klein G., Morrow R. H., Munube G. M., Pike P. Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst. 1969 Nov;43(5):1147–1157. [PubMed] [Google Scholar]
  12. Henle G., Henle W., Klein G., Gunven P., Clifford P., Morrow R. H., Ziegler J. L. Antibodies to early Epstein-Barr virus-induced antigens in Burkitt's lymphoma. J Natl Cancer Inst. 1971 Apr;46(4):861–871. [PubMed] [Google Scholar]
  13. Henle W., Henle G., Gunvén P., Klein G., Clifford P., Singh S. Patterns of antibodies to Epstein-Barr virus-induced early antigens in Burkitt's lymphoma. Comparison of dying patients with long-term survivors. J Natl Cancer Inst. 1973 May;50(5):1163–1173. doi: 10.1093/jnci/50.5.1163. [DOI] [PubMed] [Google Scholar]
  14. Henle W., Henle G., Niederman J. C., Klemola E., Haltia K. Antibodies to early antigens induced by Epstein-Barr virus in infectious mononucleosis. J Infect Dis. 1971 Jul;124(1):58–67. doi: 10.1093/infdis/124.1.58. [DOI] [PubMed] [Google Scholar]
  15. Klein G., Clifford P., Henle G., Henle W., Geering G., Old L. J. EBV-associated serological patterns in a Burkitt lymphoma patient during regression and recurrence. Int J Cancer. 1969 Jul 15;4(4):416–421. doi: 10.1002/ijc.2910040406. [DOI] [PubMed] [Google Scholar]
  16. Klein G., Clifford P., Klein E., Smith R. T., Minowada J., Kourilsky F. M., Burchenal J. H. Membrane immunofluorescence reactions of Burkitt lymphoma cells from biopsy specimens and tissue cultures. J Natl Cancer Inst. 1967 Nov;39(5):1027–1044. [PubMed] [Google Scholar]
  17. Mukojima T., Gunvén P., Klein G. Brief communication: circulating antigen-antibody complex associated with Epstein-Barr virus in recurrent Burkitt's lymphoma. J Natl Cancer Inst. 1973 Oct;51(4):1319–1321. doi: 10.1093/jnci/51.4.1319. [DOI] [PubMed] [Google Scholar]
  18. Nadkarni J. S., Nadkarni J. J., Klein G., Henle W., Henle G., Clifford P. EB viral antigens in Burkitt tumor biopsies and early cultures. Int J Cancer. 1970 Jul 15;6(1):10–17. doi: 10.1002/ijc.2910060103. [DOI] [PubMed] [Google Scholar]
  19. Reedman B. M., Klein G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer. 1973 May;11(3):499–520. doi: 10.1002/ijc.2910110302. [DOI] [PubMed] [Google Scholar]
  20. Silvestre D., Kourilsky F. M., Klein G., Yata Y., Neauport-Sautes C., Levy J. P. Relationship between the EBV-associated membrane antigen on Burkitt lymphoma cells and the viral envelope, demonstrated by immunoferritin labelling. Int J Cancer. 1971 Sep 15;8(2):222–233. doi: 10.1002/ijc.2910080206. [DOI] [PubMed] [Google Scholar]
  21. Sjögren H. O., Hellström I., Bansal S. C., Hellström K. E. Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes. Proc Natl Acad Sci U S A. 1971 Jun;68(6):1372–1375. doi: 10.1073/pnas.68.6.1372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. zur Hausen H., Schulte-Holthausen H., Klein G., Henle W., Henle G., Clifford P., Santesson L. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature. 1970 Dec 12;228(5276):1056–1058. doi: 10.1038/2281056a0. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES